1. Home
  2. PHVS vs CMRE Comparison

PHVS vs CMRE Comparison

Compare PHVS & CMRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHVS
  • CMRE
  • Stock Information
  • Founded
  • PHVS 2015
  • CMRE 1974
  • Country
  • PHVS Switzerland
  • CMRE Monaco
  • Employees
  • PHVS N/A
  • CMRE N/A
  • Industry
  • PHVS Biotechnology: Pharmaceutical Preparations
  • CMRE Marine Transportation
  • Sector
  • PHVS Health Care
  • CMRE Consumer Discretionary
  • Exchange
  • PHVS Nasdaq
  • CMRE Nasdaq
  • Market Cap
  • PHVS 1.6B
  • CMRE 1.8B
  • IPO Year
  • PHVS 2021
  • CMRE 2010
  • Fundamental
  • Price
  • PHVS $24.95
  • CMRE $15.31
  • Analyst Decision
  • PHVS Buy
  • CMRE Hold
  • Analyst Count
  • PHVS 7
  • CMRE 1
  • Target Price
  • PHVS $37.00
  • CMRE $12.00
  • AVG Volume (30 Days)
  • PHVS 282.9K
  • CMRE 549.4K
  • Earning Date
  • PHVS 11-12-2025
  • CMRE 11-04-2025
  • Dividend Yield
  • PHVS N/A
  • CMRE 3.04%
  • EPS Growth
  • PHVS N/A
  • CMRE N/A
  • EPS
  • PHVS N/A
  • CMRE 2.51
  • Revenue
  • PHVS N/A
  • CMRE $2,085,335,000.00
  • Revenue This Year
  • PHVS N/A
  • CMRE N/A
  • Revenue Next Year
  • PHVS N/A
  • CMRE N/A
  • P/E Ratio
  • PHVS N/A
  • CMRE $6.06
  • Revenue Growth
  • PHVS N/A
  • CMRE 41.07
  • 52 Week Low
  • PHVS $11.51
  • CMRE $6.63
  • 52 Week High
  • PHVS $26.33
  • CMRE $15.42
  • Technical
  • Relative Strength Index (RSI)
  • PHVS 57.14
  • CMRE 75.56
  • Support Level
  • PHVS $23.76
  • CMRE $14.24
  • Resistance Level
  • PHVS $26.20
  • CMRE $15.00
  • Average True Range (ATR)
  • PHVS 1.77
  • CMRE 0.44
  • MACD
  • PHVS 0.19
  • CMRE 0.06
  • Stochastic Oscillator
  • PHVS 75.19
  • CMRE 94.81

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

About CMRE Costamare Inc. $0.0001 par value

Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and among others. Costamare provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.

Share on Social Networks: